DSP
Why More Product Upstream Creates New Pressure Downstream
Pharma's Almanac
PAO-09-26-PA-15Sep 21, 2026
BsAbs in Oncology
Bispecific Antibodies Move Into the Heme-Onc Mainstream
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-26-PA-12Sep 16, 2026
Biosimilars
The Global Division of Labor Behind the Coming Oncology Biosimilar Wave
Pharma's Almanac
PAO-09-26-PA-18Sep 15, 2026
Partnership
Samsung Biologics Signs USD 262 Million Manufacturing Agreement with European Pharmaceutical Company
Samsung Biologics
PR-09-26-02Sep 10, 2026
Single-Use
The Changing Economics of Single-Use Biomanufacturing
Pharma's Almanac
PAO-09-26-PA-08Sep 10, 2026
Biologics Platform
Platform-Based Drug Substance Development: Applying Prior Knowledge Across Modalities
Mathias Kahl
IDT Biologika
PAO-08-26-CL-03Sep 9, 2026
Productivity
The Next Productivity Leap in Mammalian Cell Culture
Pharma's Almanac
PAO-09-26-PA-03Sep 3, 2026
Funding
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
Samsung Biologics
PR-08-26-03Sep 1, 2026
Capacity
Is the Bioreactor Arms Race Over?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-26-PA-01Sep 1, 2026
Lipase Risk
An Integrated Analytical Approach to Lipase Risk Management in Biologics Development
Kyeyeon Hur, Ph.D.; Jimin Kim, Ph.D.; Minjeong Lee; Soojeong Oh; Woojung Jun
Samsung Biologics
PAO-08-26-CL-10Aug 31, 2026
Prevention
Preventive Therapeutics Beyond Vaccines
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-13Aug 18, 2026
Masked Antibody
Expanding the Oncology Therapeutic Window Through Masked Antibody Technology
Sean McCarthy, Ph.D; David Alvaro, Ph.D.
CytomX Therapeutics
PAO-08-26-CL-09Aug 14, 2026
Self-Injection
The Quiet Revolution in How We Take Our Medicine
Ravi Kumar
OneSource Specialty Pharma
PAO-08-26-CL-06Aug 6, 2026
Critical Materials
Securing Critical Materials for Resilient Biopharmaceutical Manufacturing
Pharma's Almanac
PAO-08-26-PA-04Aug 6, 2026
Vaccines
The Next Generation of Vaccine Platforms
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-01Aug 3, 2026
AI-Optimized CLD
From Screening to Design: Can Production Cell Lines Become Programmable Platforms?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-19Jul 20, 2026
Drug–Device
Designing Formulations Around Devices Rather Than Vice Versa
Pharma's Almanac
PAO-07-26-PA-04Jul 7, 2026
Protein Conformation
Designing Drugs Against Moving Proteins: Drug Discovery Enters the Era of Protein Conformational Ensembles
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-17Jul 6, 2026
Cell-Free Synthesis
Cell-Free Biomanufacturing and the Future of Flexible Biologics Production
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-24Jun 15, 2026
Digital Sampling
Enhancing Quality and Environmental Monitoring Efficiency Through Paperless Sampling
Jiwoon Kim; Neulbit Kim; Hyeonjung Park
Samsung Biologics
PAO-06-26-CL-01Jun 10, 2026